thecompounder.com
FDA Announces Shortage of Makena (Progesterone) Injection
The FDA has announced a nationwide shortage of The commercial version of Hydroxyprogesterone Caproate Injection (aka, 17P). The trade name is Makena. 17P injection has been demonstrated to reduce the risk of preterm birth in women who have a history of delivering less than 37 weeks. Special compounding pharmacies have been safely making this sterile preparation since